These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 36300277

  • 1. Evaluating gliclazide for the treatment of type 2 diabetes mellitus.
    Tomlinson B, Li YH, Chan P.
    Expert Opin Pharmacother; 2022 Dec; 23(17):1869-1877. PubMed ID: 36300277
    [Abstract] [Full Text] [Related]

  • 2. The role of sulfonylureas in the treatment of type 2 diabetes.
    Tomlinson B, Patil NG, Fok M, Chan P, Lam CWK.
    Expert Opin Pharmacother; 2022 Feb; 23(3):387-403. PubMed ID: 34758676
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas.
    Harrower AD.
    J Diabetes Complications; 1994 Feb; 8(4):201-3. PubMed ID: 7833494
    [Abstract] [Full Text] [Related]

  • 6. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
    Rustenbeck I.
    Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
    [Abstract] [Full Text] [Related]

  • 7. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
    Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, Novials A, Rottiers R, Rutten GE, Shaw KM.
    Eur J Clin Invest; 2004 Aug; 34(8):535-42. PubMed ID: 15305887
    [Abstract] [Full Text] [Related]

  • 8. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G, Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group, Italian Diabetes Society.
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
    Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR.
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):43-51. PubMed ID: 25466239
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
    Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, Houweling ST, Bilo HJ, Kleefstra N.
    PLoS One; 2014 Jan; 9(2):e82880. PubMed ID: 24533045
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Comparison of gliclazide vs linagliptin on hypoglycemia and cardiovascular events in type 2 diabetes mellitus: A systematic review.
    Mohan V, Wangnoo S, Das S, Dhediya R, Gaurav K.
    World J Diabetes; 2022 Dec 15; 13(12):1168-1183. PubMed ID: 36578872
    [Abstract] [Full Text] [Related]

  • 15. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Khalangot M, Tronko M, Kravchenko V, Kovtun V.
    Diabetes Res Clin Pract; 2009 Dec 15; 86(3):247-53. PubMed ID: 19796836
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparing kidney outcomes in type 2 diabetes treated with different sulphonylureas in real-life clinical practice.
    Lee YH, Lee CJ, Lee HS, Choe EY, Lee BW, Ahn CW, Cha BS, Lee HC, Balkau B, Kang ES.
    Diabetes Metab; 2015 Jun 15; 41(3):208-15. PubMed ID: 25687901
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.